

Special Issue

Vaccines Against Swine Respiratory Diseases

Message from the Guest Editor

Porcine respiratory disease complex (PRDC) is a multifaceted illness caused by a mix of viral and bacterial pathogens, environmental conditions, and management practices. Several key pathogens are associated with PRDC, including porcine circovirus 2 (PCV2), porcine reproductive and respiratory syndrome virus (PRRSV), and mycoplasma. Several other pathogens have been linked to PRDC, such as PCV3, PCV4, the swine influenza virus (SIV), porcine respiratory coronavirus (PRCV), porcine cytomegalovirus (PCMV), porcine parainfluenza virus 1 (PPV1), and swine orthopneumovirus (SOV). With regard to bacteria, *Actinobacillus pleuropneumoniae*, *Glasserella parasuis*, and *Bordetella bronchiseptica* have been implicated. Swine farming practices have evolved, resulting in a higher density, which has led to a higher prevalence of PRDC. In response, substantial efforts are being made to improve and develop new vaccine platforms. The goal of this Special Issue is to collate original research focused on the development and evaluation of vaccines for PRDC. We welcome the submission of original research articles and reviews.

Guest Editor

Prof. Dr. Jairo Jaime

Animal Health Department, Center of Infectious Diseases and Veterinary Immunology, College of Veterinary Medicine and Production Animal, Colombia National University, Bogotá, Colombia

Deadline for manuscript submissions

28 February 2027



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/248846

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).